# A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

> **NCT03178552** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1000 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Atezolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Entrectinib
- **DRUG:** Cobimetinib
- **DRUG:** Vemurafenib
- **DRUG:** Bevacizumab
- **DRUG:** Divarasib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03178552
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-22
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178552, "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03178552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*